IP Library Patent Application 17559545
Patent Application
App. No. 17/559,545

METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/559,545
Abstract

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Claims (19)

1 . A culture of an isolated cell prepared by a process comprising:

placing a subepithelial layer of a mammalian umbilical cord tissue in direct contact with a growth substrate; and

culturing the subepithelial layer such that the isolated cell from the subepithelial layer is capable of self-renewal and culture expansion, wherein culturing comprises culturing in a culture media that is free of animal components,

wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and

wherein the isolated cell does not express NANOG and at least five cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

2 . The culture of claim 1 , wherein the isolated cell expresses CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, and CD105.

3 . The culture of claim 1 , wherein the isolated cell does not express CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, and HLA-DR.

4 . The culture of claim 1 , wherein the isolated cell is positive for SOX2.

5 . The culture of claim 1 , wherein the isolated cell is positive for OCT4.

6 . The culture of claim 1 , wherein the isolated cell is positive for SOX2 and OCT4.

7 . The culture of claim 1 , wherein the wherein the isolated cell is capable of differentiation into a cell type selected from the group consisting of adipocytes, chondrocytes, osteocytes, cardiomyocytes, endothelial cells, and myocytes.

8 . The culture of claim 1 , wherein the isolated cell produces exosomes expressing CD63, CD9, or CD63 and CD9.

9 . The culture of claim 1 , wherein placing and culturing the subepithelial layer is performed without the use of any enzyme.

10 . A culture of differentiated cells derived from the culture of the isolated cell of claim 1 , wherein the culture of differentiated cells includes a cell type selected from the group consisting of adipocytes, chondrocytes, osteocytes, cardiomyocytes, endothelial cells, myocytes and combinations thereof.

11 . The culture of claim 1 that has been differentiated into a culture of adipocyte cells.

12 . The culture of claim 1 that has been differentiated into a culture of chondrocyte cells.

13 . The isolated cell of claim 1 that has been differentiated into a culture of osteocyte cells.

14 . The culture of claim 1 that has been differentiated into a culture of cardiomyocyte cells.

15 . The culture of claim 1 that has been differentiated into a culture of myocyte cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2023
From: PATEL, AMIT
To: JADI CELL LLC
Reel/Frame 063045/0145 →